Thank you, Mr. Chair. Thank you for the question, Ms. Harder.
I think your question points out something really important: it's not necessarily the therapy; it's the people. People are very complex. They react differently to different molecules, to different treatments.
Mr. Keon's point is correct. Health Canada regulates for safety and efficacy. In all cases, generic drugs are safe and efficacious. However, sometimes you put different therapies into different people and they react differently. That raises a very important point, one of subsequent entry biologics or the biosimilars. While, yes, they are all deemed safe and efficacious by Health Canada, they are very complex molecules and they will behave differently in different people. That's why the physician-patient dialogue is an extremely important one.
I cannot comment on the specifics of the case you mentioned, but I think that it would be one where you have to better understand what the physician is also seeing.